What an opportunity the Admedus TAVR device presents, such compelling reasons predicting its future success....
An ADAPT treated valve which has shown not to calcify (10 years of data,) a one piece valve replicating a natural aortic valve as opposed to the standard 3 leaflet valve everyone else has, 15 sutures (stitches) compared to 150-160 again making the device far more closely replicate the natural valve AND dramatically lowering production costs, pre-packaged in a sterile fluid reducing preparation time by around 45 minutes saving each doctor performing TAVR ops potentially thousands of hours over the course of a number of years....
And the best thing of all is that we have an incredible CEO and COO leading the project. Both highly qualified, highly determined WINNERS with long track records of SUCCESS.
Very very exciting.
What an opportunity the Admedus TAVR device presents, such...
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.65 |
Change
-0.060(0.38%) |
Mkt cap ! $300.8M | |||
| Open | High | Low | Value | Volume |
| $15.72 | $15.85 | $15.51 | $1.660M | 117.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 312 | $15.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.65 | 626 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |